Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/167124 |
Resumo: | Many researchers have shown that pretreatment plasma fibrinogen levels are closely correlated with the prognosis of patients with lung cancer (LC). In this study, we thus performed a meta-analysis to systematically assess the prognostic value of pretreatment plasma fibrinogen levels in LC patients. A computerized systematic search in PubMed, EMBASE, Web of Science and China National Knowledge Infrastructure (CNKI) was performed up to March 15, 2018. Studies with available data on the prognostic value of plasma fibrinogen in LC patients were eligible for inclusion. The pooled hazard ratios (HRs) and odd ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the correlation between pretreatment plasma fibrinogen levels and prognosis as well as clinicopathological characteristics. A total of 17 studies with 6,460 LC patients were included in this meta-analysis. A higher pretreatment plasma fibrinogen level was significantly associated with worse overall survival (OS) (HR: 1.57; 95% CI: 1.39-1.77; p=0.001), disease-free survival (DFS) (HR: 1.53; 95% CI: 1.33-1.76; p=0.003), and progression-free survival (PFS) (HR: 3.14; 95% CI: 2.15-4.59; po0.001). Furthermore, our subgroup and sensitivity analyses demonstrated that the pooled HR for OS was robust and reliable. In addition, we also found that a higher fibrinogen level predicted advanced TNM stage (III-IV) (OR=2.18, 95% CI: 1.79-2.66; po0.001) and a higher incidence of lymph node metastasis (OR=1.74, 95% CI: 1.44-2.10; p=0.02). Our study suggested that higher pretreatment plasma fibrinogen levels predict worse prognoses in LC patients. |
id |
USP-19_bc58af8420b9cc44daf12bdc787e28bb |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/167124 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancerPretreatment Plasma FibrinogenLung CancerPrognosisMeta-AnalysisMany researchers have shown that pretreatment plasma fibrinogen levels are closely correlated with the prognosis of patients with lung cancer (LC). In this study, we thus performed a meta-analysis to systematically assess the prognostic value of pretreatment plasma fibrinogen levels in LC patients. A computerized systematic search in PubMed, EMBASE, Web of Science and China National Knowledge Infrastructure (CNKI) was performed up to March 15, 2018. Studies with available data on the prognostic value of plasma fibrinogen in LC patients were eligible for inclusion. The pooled hazard ratios (HRs) and odd ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the correlation between pretreatment plasma fibrinogen levels and prognosis as well as clinicopathological characteristics. A total of 17 studies with 6,460 LC patients were included in this meta-analysis. A higher pretreatment plasma fibrinogen level was significantly associated with worse overall survival (OS) (HR: 1.57; 95% CI: 1.39-1.77; p=0.001), disease-free survival (DFS) (HR: 1.53; 95% CI: 1.33-1.76; p=0.003), and progression-free survival (PFS) (HR: 3.14; 95% CI: 2.15-4.59; po0.001). Furthermore, our subgroup and sensitivity analyses demonstrated that the pooled HR for OS was robust and reliable. In addition, we also found that a higher fibrinogen level predicted advanced TNM stage (III-IV) (OR=2.18, 95% CI: 1.79-2.66; po0.001) and a higher incidence of lymph node metastasis (OR=1.74, 95% CI: 1.44-2.10; p=0.02). Our study suggested that higher pretreatment plasma fibrinogen levels predict worse prognoses in LC patients.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2020-02-28info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/xmlhttps://www.revistas.usp.br/clinics/article/view/16712410.6061/clinics/2020/e993Clinics; v. 75 (2020); e993Clinics; Vol. 75 (2020); e993Clinics; Vol. 75 (2020); e9931980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/167124/159564https://www.revistas.usp.br/clinics/article/view/167124/159565Copyright (c) 2020 Clinicsinfo:eu-repo/semantics/openAccessZhang, YiCao, JunyanDeng, YinanHuang, YimingLi, RongLin, GuozhenDong, MinHuang, Zenan2020-02-28T11:26:48Zoai:revistas.usp.br:article/167124Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2020-02-28T11:26:48Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer |
title |
Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer |
spellingShingle |
Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer Zhang, Yi Pretreatment Plasma Fibrinogen Lung Cancer Prognosis Meta-Analysis |
title_short |
Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer |
title_full |
Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer |
title_fullStr |
Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer |
title_full_unstemmed |
Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer |
title_sort |
Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer |
author |
Zhang, Yi |
author_facet |
Zhang, Yi Cao, Junyan Deng, Yinan Huang, Yiming Li, Rong Lin, Guozhen Dong, Min Huang, Zenan |
author_role |
author |
author2 |
Cao, Junyan Deng, Yinan Huang, Yiming Li, Rong Lin, Guozhen Dong, Min Huang, Zenan |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Zhang, Yi Cao, Junyan Deng, Yinan Huang, Yiming Li, Rong Lin, Guozhen Dong, Min Huang, Zenan |
dc.subject.por.fl_str_mv |
Pretreatment Plasma Fibrinogen Lung Cancer Prognosis Meta-Analysis |
topic |
Pretreatment Plasma Fibrinogen Lung Cancer Prognosis Meta-Analysis |
description |
Many researchers have shown that pretreatment plasma fibrinogen levels are closely correlated with the prognosis of patients with lung cancer (LC). In this study, we thus performed a meta-analysis to systematically assess the prognostic value of pretreatment plasma fibrinogen levels in LC patients. A computerized systematic search in PubMed, EMBASE, Web of Science and China National Knowledge Infrastructure (CNKI) was performed up to March 15, 2018. Studies with available data on the prognostic value of plasma fibrinogen in LC patients were eligible for inclusion. The pooled hazard ratios (HRs) and odd ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the correlation between pretreatment plasma fibrinogen levels and prognosis as well as clinicopathological characteristics. A total of 17 studies with 6,460 LC patients were included in this meta-analysis. A higher pretreatment plasma fibrinogen level was significantly associated with worse overall survival (OS) (HR: 1.57; 95% CI: 1.39-1.77; p=0.001), disease-free survival (DFS) (HR: 1.53; 95% CI: 1.33-1.76; p=0.003), and progression-free survival (PFS) (HR: 3.14; 95% CI: 2.15-4.59; po0.001). Furthermore, our subgroup and sensitivity analyses demonstrated that the pooled HR for OS was robust and reliable. In addition, we also found that a higher fibrinogen level predicted advanced TNM stage (III-IV) (OR=2.18, 95% CI: 1.79-2.66; po0.001) and a higher incidence of lymph node metastasis (OR=1.74, 95% CI: 1.44-2.10; p=0.02). Our study suggested that higher pretreatment plasma fibrinogen levels predict worse prognoses in LC patients. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-02-28 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/167124 10.6061/clinics/2020/e993 |
url |
https://www.revistas.usp.br/clinics/article/view/167124 |
identifier_str_mv |
10.6061/clinics/2020/e993 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/167124/159564 https://www.revistas.usp.br/clinics/article/view/167124/159565 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2020 Clinics info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2020 Clinics |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/xml |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; v. 75 (2020); e993 Clinics; Vol. 75 (2020); e993 Clinics; Vol. 75 (2020); e993 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1787713181523640320 |